bosentan anhydrous has been researched along with Necrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antus, B; Fillinger, J; Horvath, I; Jeney, C; Sebe, A | 1 |
| Fain, O | 1 |
| Hvaal, K; Mathisen, SR; Nordsletten, L; Skjeldal, S; Svindland, A | 1 |
3 other study(ies) available for bosentan anhydrous and Necrosis
| Article | Year |
|---|---|
Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Bosentan; Bronchiolitis Obliterans; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelins; Gene Expression Regulation; Male; Necrosis; Platelet-Derived Growth Factor; Ramipril; Rats; Rats, Inbred BN; Rats, Inbred Lew; Receptors, Endothelin; Renin-Angiotensin System; RNA, Messenger; Sulfonamides; Trachea; Transforming Growth Factor beta1; Transplantation, Homologous | 2006 |
[Digital necrosis in scleroderma].
Topics: Adult; Bosentan; Endothelin Receptor Antagonists; Female; Fingers; Humans; Iloprost; Necrosis; Platelet Aggregation Inhibitors; Recurrence; Scleroderma, Systemic; Sulfonamides; Vasodilator Agents | 2007 |
Protective effect of the endothelin antagonist Bosentan against ischemic skeletal muscle necrosis.
Topics: Animals; Bosentan; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Laser-Doppler Flowmetry; Leukocyte Count; Male; Muscle, Skeletal; Necrosis; Neutrophils; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Time Factors | 1999 |